The novel biparatopic anti-HER2 antibody–tubulin conjugate (bHER2-ATC) has been investigated in a preclinical murine BC model with BMs, showing the increased uptake of the agent by endocytosis and suggesting a possible effective mechanism of brain penetration [132]. The gene discussed is ERBB2; the disease is breast cancer.